Search results
Results from the WOW.Com Content Network
Ouchterlony double immunodiffusion (also known as passive double immunodiffusion) is an immunological technique used in the detection, identification and quantification of antibodies and antigens, such as immunoglobulins and extractable nuclear antigens.
You are free: to share – to copy, distribute and transmit the work; to remix – to adapt the work; Under the following conditions: attribution – You must give appropriate credit, provide a link to the license, and indicate if changes were made.
Immunodiffusion is a laboratory technique used to detect and quantify antigens and antibodies by observing their interactions within a gel medium. [1] This technique involves the diffusion of antigens and antibodies through a gel, usually agar, resulting in the formation of a visible precipitate when they interact.
The six main antigens used in immunological laboratories for detection are Ro, La, Sm, RNP, Scl-70 and Jo1, [7] which are screened for by Ouchterlony double immuno diffusion techniques and confirmed by immunoblotting. On anti-nuclear antibody tests, these antigens have a speckled pattern. [8]
Counter-immunoelectrophoresis and its modification. In comparison to other conventional methods of diagnosis e.g. for viral infection testing, counter-immunoelectrophoresis is a highly specific, simple, and speedy method that does not require sophisticated, expensive tools, input materials, or long-term capacity building.
A solution containing antibody is added to a heated medium such as agar or agarose dissolved in buffered normal saline.The molten medium is then poured onto a microscope slide or into an open container, such as a Petri dish, and allowed to cool and form a gel.
Örjan Thomas Ouchterlony (January 14, 1914, Stockholm – September 25, 2004) was a Swedish bacteriologist and immunologist who is credited with the creation of the Ouchterlony double immuno diffusion test in the 1940s. [1] [2] He was trained at Karolinska Institute, where his received his medical doctorate.
The first [8] came from transplant surgeons who conducted a prospective randomized, double-blind, placebo-controlled trial. Administration of recombinant human superoxide dismutase (rh-SOD) in recipients of cadaveric renal allografts demonstrated prolonged patient and graft survival with improvement in both acute and chronic rejection events.